A Study to Assess the Efficacy and Safety of MNK-1411 in Duchenne Muscular Dystrophy

PHASE2TerminatedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

July 27, 2018

Primary Completion Date

February 25, 2020

Study Completion Date

February 25, 2020

Conditions
Muscular Dystrophy, Duchenne
Interventions
DRUG

MNK-1411

MNK-1411 (1 mg/mL suspension) for subcutaneous injection

OTHER

Placebo

Placebo suspension for subcutaneous injection

Trial Locations (16)

1431

University Multiprofile Hospital for Active Treatment Aleksandrovska EAD, Sofia

11000

Clinic of Neurology and Psychiatry for Children and Youth, Belgrade

20132

Ospedale San Raffaele S.r.l. - PPDS, Milan

30318

Rare Disease Research, LLC, Atlanta

32561

NW FL Clinical Research Group, LLC, Gulf Breeze

33343

Mersin Universitesi Tip Fakultesi Hastanesi, Mersin

34000

Instituto de Investigaciones Aplicadas a la Neurociencia A.C., Durango

37232

Monroe Carell Jr Childrens Hospital at Vanderbilt, Nashville

44280

Hospital Civil Fray Antonio Alcalde, Guadalajara

46026

Hospital Universitari i Politecnic La Fe Valencia, Valencia

75207

University of Texas Southwestern Medical Center, Dallas

78229

UT Health Science Center, San Antonio, San Antonio

80020

Neurociencias Estudios Clinicos S.C., Culiacán

5810001

Edith Wolfson Medical Center, Holon

08025

Hospital de La Santa Creu i Sant Pau, Barcelona

08950

Hospital Sant Joan de Deu - PIN, Esplugues de Llobregat

Sponsors
All Listed Sponsors
lead

Mallinckrodt ARD LLC

INDUSTRY